Literature DB >> 28744657

Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28744657     DOI： 10.1007/s00417-017-3749-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

Review 1.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

2.  Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2017-02-09       Impact factor: 5.258

3.  Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-30       Impact factor: 3.117

4.  Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2017-03-17       Impact factor: 3.775

5.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

6.  Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study.

Authors:  Irini Chatziralli; George Theodossiadis; Stamatina A Kabanarou; Efstratios Parikakis; Tina Xirou; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-15       Impact factor: 3.117

7.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li
Journal:  Ophthalmology       Date:  2011-07-20       Impact factor: 12.079

8.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

9.  Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Authors:  Sandeep Grover; Ravi K Murthy; Vikram S Brar; Kakarla V Chalam
Journal:  Am J Ophthalmol       Date:  2009-05-09       Impact factor: 5.258

10.  Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion.

Authors:  Baruch D Kuppermann; Julia A Haller; Francesco Bandello; Anat Loewenstein; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Retina       Date:  2014-09       Impact factor: 4.256
  10 in total
  1 in total

1.  Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management.

Authors:  Dan Călugăru; Mihai Călugăru; Ştefan Ţălu
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.